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http://dx.doi.org/10.1016/j.jmii.2012Background: We previously constructed a recombinant bacille Calmette-Gue´rin (rBCG-AE)
strain that could express a fused Ag85A-ESAT-6 protein. That study suggested that the rBCG-
AE strain was able to induce a higher titer of antibody and elicit a more long-lived and stronger
Th1-type cellular immune responses than the parental BCG strain, the rBCG-A strain (i.e.,
expressing Ag85A), or the rBCG-E strain (i.e., expressing ESAT-6).
Methods: In the current study, we further investigated the strain’s protective efficacy against
Mycobacterium tuberculosis H37Rv infection in BALB/c mice through evaluating organ bacte-
rial loads, lung histopathology, lung immunohistochemistry, and net weight gain or loss by
using conventional BCG, rBCG-A, and rBCG-E as the controls.
Results: From the 3rd to 9th weeks after the challenge infection, the bacterial counts were
significantly lower in tissues (e.g., spleen and lung tissues) in the mice immunized with
rBCG-AE than in the control group, but were higher than the counts in the BCG group. The
pathological damage in the lung tissues of the rBCG-AE group gradually improved from the
6th to 9th weeks after being infected with M. tuberculosis H37Rv, but the score of pathological
changes in the rBCG-AE group was obviously higher than the score in the BCG group. There was
no difference in the percentage of IFN-g and iNOS positive cells in the lung tissues of the rBCG-
AE and BCG groups.
Conclusion: The results suggest that rBCG-AE can not promote protective efficacy against M.
tuberculosis H37Rv infection, compared to the BCG vaccine.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Human Anatomy, College of Preclinical Medicine, Dali University, Dali 671000, China.
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Tuberculosis (TB) is a serious disease afflicting humans; it
results in millions of deaths and new cases each year.1,2 The
only available vaccine against TB is attenuated Mycobac-
terium bovis bacille Calmette-Gue´rin (BCG). However, the
protective efficacy of BCG against TBdespecially adult
TBdremains controversial.3 A more efficacious and satis-
factory vaccine to fight against TB is therefore urgently
required.
Studies have been performed in past decades to develop
novel TB vaccines such as rBCG vaccines,4,5 live attenuated
vaccines,6 subunit vaccines,7 and DNA vaccines.8 However,
no vaccine has exceeded BCG in conferring protection from
Mycobacterium tuberculosis infection in mankind.
Recombinant BCG (rBCG) is a promising approach to
promote the immune efficacy of the BCG vaccine by
importing exogenous genes that encode immunodominant
antigens of M. tuberculosis or immunoregulatory cytokines.
By rBCG technology, the proteins secreted by BCG and
recombinant proteins introduced to BCG can simulta-
neously stimulate the body to generate stronger immune
responses to M. tuberculosis infection. The rBCG vaccine
shares many advantages of the BCG vaccine such as safety
and low adverse effects. It can be vaccinated in the form of
a viable organism and it is capable of longterm self-
production in the body,9 allowing it to stimulate sustained
immune responses against M. tuberculosis infection. In
recent years, studies for developing a better TB vaccine
than BCG have therefore been focused on the rBCG
vaccine.
Early secretory antigen target 6 (ESAT-6) is only present
in the virulent M. tuberculosis, but is lacking in BCG.10 It
can induce strong cell-mediated immunity.11,12 It has been
considered a protective antigen for developing TB
vaccines.13 Ag85A is a major fraction of the Ag85 complex
(which comprises Ag85A, Ag85B, and Ag85C). These AG85
components are proteins that are secreted in M. tubercu-
losis culture filtrate.14,15 Ag85A is the most essential
component of M. tuberculosis for immunostimulation and
has been used in numerous vaccine preparations that can
induce outstanding protective efficacy.16 Ag85A, moreover,
is closely correlated with the longterm survival of M.
tuberculosis within macrophages.17 M. tuberculosis within
macrophages may be effectively eliminated when the
immune responses against Ag85A are induced. For these
reasons, we previously chose Ag85A and ESAT-6 to construct
rBCG (rBCG-AE) for stimulating more potent immune
responses against M. tuberculosis infection; the study
showed that in BALB/c mice the vaccine was able to induce
a higher titer of antibody, elicit a greater CD4þ T and CD8þ
T proliferation rate of splenocytes, and elevate the level of
interferon-gamma (IFN-g) production, compared to the
parental BCG. The study suggested that the immunoge-
nicity of the parental BCG was significantly improved.18
Eliciting prominent immunogenicity is insufficient for
a satisfactory TB vaccine. Our ultimate goal is to develop
a vaccine that effectively prevents M. tuberculosis infec-
tion. In the current study, we therefore further evaluated
the protective efficacy conferred by rBCG-AE vaccine
against M. tuberculosis H37Rv infection in BALB/c mice.Materials and methods
Bacterial strains and media
M. bovis BCG-China was obtained from the Chengdu Bio-
logical Products Institute (Chengdu, China). M. tuberculosis
H37Rv (strain ATCC 93009) was originally conserved in the
Animal Bio-Safety Level 3 (ABSL-3) facility of Wuhan
University (Wuhan, China). The rBCG vaccines were previ-
ously constructed and included rBCG-AE (which expresses
the Ag85A-ESAT-6 fusion protein), rBCG-A (which only
expresses the Ag85A protein of M. tuberculosis), rBCG-E
(which only expresses the ESAT-6 protein of M. tubercu-
losis) and rBCG-361(BCG strains transformed with pMV361
plasmids).18 They were cultivated in Sauton medium (i.e.,
0.5 g MgSO4, 0.5 g K2HPO4, 2 g citric acid, 8 g sodium
glutamate, 60 mL glycerol, 0.01 g ZnSO4, and 0.05 g ferrum-
ammonium citrate in 1000 mL at a pH7 ranging approxi-
mately from 4 to 7.5).
Animals
Pathogen-free BALB/c female mice were obtained from the
Laboratory Animal Research Center, Second Military
Medical University (Shanghai, China). The mice were 4e5
weeks old at the time of vaccination. All of the animals
were housed under controlled conditions at the ABSL-3
facility of Wuhan University (Wuhan, China). The animals
were managed by using welfare animal practices.
Animal immunization
Fifty-four female BALB/c mice were randomly divided into
6 groups: (1) phosphate-buffered salineeTween-80 (PBST)
group; (2) BCG group; (3) rBCG-361 group; (4) rBCG-E group;
(5) rBCG-A group; and (6) rBCG-AE group. The mice were
immunized subcutaneously with either BCG or rBCG vaccine
at a dose of 5  106 colony-forming units (CFUs), which was
suspended in PBST (0.01M PBS containing 0.05% Tween-80,
V/V) (Sigma, St. Louis, MO) in a volume of 0.1 mL. The
control animals (i.e., PBST group) were sham-immunized
with PBST only. All animals were immunized once. The
protective experiment was performed at 10 weeks after
vaccination.
Challenge infection
Ten weeks after immunization, the mice (nine mice per
group) were infected intravenously (i.v.) via the lateral tail
vein with 1  106 CFUs of virulent M. tuberculosis H37Rv.
Three mice in each group were sacrificed at 3 weeks, 6
weeks, and 9 weeks after the challenge to evaluate the
respective protective efficacy. The mice were weighed
before being killed. The spleen and lung tissues from
immunized mice were removed aseptically. One-half of the
spleen (v/v) and the right lung lobe from each mouse were
used for culture to determine the M. tuberculosis loads in
the tissues. The left lung and the rest half spleen tissues
were used for acid-fast staining, hematoxylin and eosin
(H&E) staining, and evaluated by light microscopy.19
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protocols were approved by the institutional animal
experimentation committee.
Colony-forming unit detection
The bacterial loads in the lung and spleen tissues were
performed 3 weeks, 6 weeks, and 9 weeks after infection
with M. tuberculosis H37Rv. The organs were removed
aseptically and washed with sterile PBS. The colony-
forming unit (CFU) was performed in serial dilutions of
the homogenate and plated onto Middlebrook 7H11þOADC
agar. The CFU could be determined 4 weeks after incuba-
tion at 37C.
Histopathological analysis
The lung tissues from the mice challenged with M. tuber-
culosis H37Rv were fixed in 10% formalin for 72 hours,
dehydrated by a graded ethanol series, embedded in
paraffin for 5-mm sections. The sections were stained with
H&E. The lung tissue sections were evaluated by acid-fast
staining to determine M. tuberculosis numbers. Patholo-
gists from the ABSL-3 facility (Wuhan, China) evaluated the
results by using the Leica system (Leica, Heidelberg,
Germany). According to observed histopathological changes
(e.g., peribronchiolitis, perivasculitis, alveolitis, and gran-
uloma formation), the lung pathology was scored as 0, 1, 2,
3, 4, or 5 for absent, minimal, slight, moderate, marked, or
strong changes, respectively; the maximum sum was 20.
Analysis of lung acid-fast stains
The M. tuberculosis number in the lung tissues was deter-
mined through acid-fast staining. A pathologist who had no
prior knowledge of the experimental groups counted the M.
tuberculosis numbers in each tissue section under a light
microscope. The pathologist evaluated the sample at least
twice to verify the reproducibility of the observations. The
M. tuberculosis number in a random area of 0.25 cm2 in
each section was counted. Five tissue sections were coun-
ted from each detected sample, the results are presented
as the mean  the standard error.
Immunohistochemistry staining for detection of the
IFN-g and iNOS expression in the lung tissues
To investigate the expression of IFNeg and inducible nitric
oxide synthase (iNOS) in lung tissues from infected mice
with M. tuberculosis, the lung tissues from challenged
animals were fixed by 10% formalin for 72 hours and were
then embedded in paraffin for 5-mm sections. The lung
sections were deparaffinized with xylene and gradually
dehydrated in ethyl alcohol. The sections were then
immersed in a citric acid buffer (pH 6.0) in a microwave
oven for 10 minutes to perform antigen retrieval. Endoge-
nous peroxidase activity and nonspecific binding were
blocked with 3% hydrogen peroxide for 15 minutes and 10%
normal goat serum for 15 minutes, respectively. Rabbit
anti-mouse IFN-g and iNOS IgG (eBioscience, San Diego, CA)
were added at a dilution of 1:200 for 1 hour at 37C by using1:200 diluted normal rabbit serum under the same condi-
tions as the negative control. Slides were then incubated
with biotinylated anti-rabbit immunoglobulin in a humidi-
fied chamber for 20 minutes. The reaction was visualized by
using the substrate diaminobenzidine (DAB). The sections
were afterward counterstained with hematoxylin. Under
a light microscope, the cytoplasm of IFN-g and iNOS posi-
tive cells was stained brown-yellow. The results were
evaluated by the percentage of positive cells. Under high-
power microscopy (magnification of 400), the number of
positive cells and the total number of cells in the lung
tissues were counted from 10 randomly selected fields in
each section. Five tissue sections were also counted from
each detected sample. All counting was manually per-
formed by an investigator who was blinded to the treat-
ment groups. The percentages are represented as the
mean  standard errors.
Statistical analysis
The measurement data are represented as the
mean  standard error. The variance comparison was made
using the Student F test. The differences were considered
statistically significant when the probability values were
less than 0.05. The statistical tests were run on SPSS soft-
ware (Version.13.0, IBM Corporation, NY, USA).
Results
Determination of bacterial loads
The lung and spleen tissues from the mice of groups were
obtained 3 weeks, 6 weeks, and 9 weeks after infection
with M. tuberculosis H37Rv to culture for bacterial coloni-
zation. Mice immunized with rBCG vaccines had a reduced
number of CFUs in the lung (Fig. 1A) and spleen tissues
(Fig. 1B), compared to the control group (i.e., PBST group).
From the 3rd to the 9th week after the challenge infection,
the bacterial count in the tissues (including the spleen and
lung tissues) of the mice immunized with BCG were signif-
icantly lower than the count in the tissues of the rBCG-AE,
rBCG-A, and rBCG-E groups. The mice in the BCG group also
gained the most weight of all the groups (Fig. 1C).
Pathological examinations
To evaluate pathological changes, lung tissues from the
mice were fixed, sectioned and stained with H&E. Three
weeks after the challenge, the lungs of the mice of each
group showed many small tubercles, a small number of
great tubercles, and alveolitis. The pathological changes
were not different among the groups. Six weeks after the
infection, extensive serious pathological changes were
present with strong peribronchiolitis, perivasculitis and
alveolitis, and several tubercles in the lungs of mice
immunized with rBCG-AE, rBCG-361, rBCG-A, rBCG-E, or
PBST. The pathological damage was comparatively much
less in the lungs of the mice vaccinated with BCG from the
6th to the 9th week after the challenge infection. Both the
extent and severity of lung pathology gradually attenuated
Figure 1. Evaluation of bacterial loads in the tissues from
mice challenged with Mycobacterium tuberculosis H37Rv and
net weight (g) gain or loss of the mice. Ten weeks after
vaccination with BCG or rBCGs, the BALB/c mice were infected
through the lateral tail vein with 1  106 colony-forming units
(CFUs) of M. tuberculosis H37Rv. At 3 weeks, 6 weeks, and 9
weeks, the number of live bacteria in (A) the lung and (B) the
spleen was determined and expressed as log10 CFU. The data
are presented as mean  the standard error. *p < 0.01.
>p < 0.05, versus the rBCG-AE, rBCG-A, or rBCG-E groups. (C)
The results of the net weight gain or loss shows that the weight
loss is even greater in the rBCG-AE group than in the BCG group
during the challenge infection, indicating that the virulence of
rBCG-AE may be increased.
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damage in alveolar tissue at the 9th week after the chal-
lenge (Fig. 2D), compared to normal lung tissue (Fig. 2A).
However, the lung sections from the PBST group showed
severe interstitial pneumonia and intense inflammation
throughout the lung (Fig. 2B). In the rBCG-AE groups, there
was still a large number of lymphocytes and inflammatory
exudates in the lung tissue at the 9th week after the
challenge infection (Fig. 2C). At the same time, the lung
pathology score in the BCG group was significantly lower
than the score in the rBCG-AE group (Fig. 2E).
Acid-fast staining
The results of acid-fast staining clearly illustrated that the
M. tuberculosis numbers in the lung and spleen tissues from
the group immunized with BCG (Fig. 3D) were lower than
their numbers in the PBST group (Fig. 3B) or rBCG-AE group
(Fig. 3C and E). This is consistent with the results of
bacterial load experiments. There was no M. tuberculosis in
the normal lung tissue (Fig. 3A).
Detection of immunohistochemistry staining
The lung tissues were stained by immunohistochemistry to
detect the amount of IFN-g and iNOS expression 3 weeks, 6
weeks, and 9 weeks after infection with Mycobacterium
tuberculosis H37Rv. Results showed that from the 3rd to the
9th week after the challenge, the percentage of cells
positive for IFN-g (Fig. 1) and iNOS (Fig. 2) were obviously
higher in the lung tissues of animals vaccinated with BCG
and rBCG vaccines than in the PBST group. There was no
statistical difference among the vaccine groups (including
the rBCG vaccine groups and BCG group).
Discussion
Previous research revealed that the rBCG-AE strain is able
to express the Ag85A-ESAT-6 fusion protein, whereas the
BCG strain could not secrete this protein. This suggests that
the rBCG-AE strain had obtained more of the stimulation
antigen. We then evaluated its immunogenicity and illus-
trated that the rBCG-AE strain could induce a higher titer of
antibody and elicit more long-lasting and stronger T helper
1 (Th1)-type cellular immune responses than the parental
BCG strain.18 In this study, To investigate the ability of the
rBCG-AE strain to defend against M. tuberculosis infection,
we further evaluated its protective efficacy in BALB/c
mice. We chose BALB/c mice because they are promising
small animal models that many related studies have used
for the preliminary evaluation of new TB vaccine candi-
dates.20,21 The protective efficacy will be further evaluated
in large animal models such as the monkey when the
immunization efficacy is confirmed as better than the
efficacy now provided by the parental BCG in BALB/c mice
models.
Compared to BCG strain, the rBCG-AE strain is able to
elicit stronger antibody responses, activate greater sple-
nocyte proliferation, and produce higher levels of IFNeg.18
To our surprise, the protective experiments in this study
showed that none of the rBCG vaccines exceeded the
Figure 2. Pathological changes in the lung tissues nine weeks after infecting the mice. (A) The normal mice (i.e., non-immunized
and non-infected). (B) The PBST group shows extensive serious pathological changes with strong peribronchiolitis, perivasculitis
and alveolitis and several tubercles are present in the lung tissues. (C) The rBCGeAE group shows a large number of lymphocytes
and inflammatory exudates. (D) The mice in the BCG group with M. tuberculosis H37Rv shows only slight damage in the alveolar
tissues, compared to these tissues in the normal mice. (E) The graph shows the scores of the lung pathology. *p < 0.01, versus other
groups. >p < 0.01, versus the PBST group.
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losis H37Rv infection. The bacterial counts in the lung and
spleen tissues from the mice immunized with rBCG-A, rBCG-
E, or rBCG-AE were significantly lower than in animals
injected with PBST, but obviously higher than in animals
vaccinated with BCG. This suggests that the parental BCG
has a greater ability to eliminate the M. tuberculosis in the
tissues (Fig. 1). This finding was further confirmed by the
results of the acid-fast staining, which illustrated that
the M. tuberculosis numbers in the spleen and lung tissues
from the group immunized with BCG were the lowest
among groups (Fig. 3). The pathological examination alsoshowed that, after M. tuberculosis H37Rv infection, the
pathological damage in the lung tissue was much less in the
BCG group than in the other groups (Fig. 2). The Th1
cytokine IFN-g is essential to immunity by preventing
damage from intracellular pathogens. It is able to activate
macrophages that inhibit or eliminate M. tuberculosis in
the lung tissue.22 The effector molecule nitric oxide (NO),
which is produced by activity of phagocytes in the lung
tissue, is enzymatically generated in immune and inflam-
matory situations by iNOS.23 The molecule iNOS plays
a crucial role in host defense against mycobacterial infec-
tions; it is activated by IFN-g.24 In our study, we therefore
Figure 3. Results of acid-fast staining. A pathologist, who had no prior knowledge of the experimental groups, evaluated the M.
tuberculosis numbers in the tissues, counted the M. tuberculosis number in a random area of 0.25 cm2 in each section, and counted
five tissue sections from each detected sample. The results are presented as the mean  the standard error. (A) There is no M.
tuberculosis in the lung tissues of normal mice. By contrast, there is a large number of M. tuberculosis in the lung tissues of (B) the
PBST group and (C) the rBCG-AE group. (D) Nine weeks after the challenge infection, M. tuberculosis numbers in the lung tissues
from the BCG group are greatly decreased, compared to the other groups. (E) The graph displays the M. tuberculosis numbers in the
lung tissues. *p < 0.01, versus other groups. >p < 0.01, versus the PBST group.
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IFN-g by measuring iNOS expression in the lung tissues.
Studies have also reported that macrophages and immune
effector cells secreting IFN-g in the lung (but not in spleen)
is able to fight against M. tuberculosis infection.25 Nitric
oxide is mainly produced by activated macrophages in the
lung tissue during pulmonary tuberculosis.26 Hence, in our
study their expression only in the lung tissues were
measured by immunohistochemistry. The results showed
that (IFN)-g and iNOS expression in the lung tissues from themice vaccinated with rBCG were similar to their expression
in mice immunized with BCG (Fig. 4). This indicated that
the rBCG vaccines were unable to improve the expression
of the molecules in the lung tissues, compared to the BCG
vaccine.
The protective efficacy of rBCG-AE should logically be
higher than the parental BCG when the immunodominant
antigens ESAT-6 and Ag85A are added into BCG. The
protective efficacy of rBCG-AE unfortunately was not
enhanced and was even lower than the parental BCG.
Figure 4. Expression of cytokines of interferon-gamma and inducible nitric oxide synthase in the lung tissues from the mice
infected with M. tuberculosis H37Rv. At 3 weeks, 6 weeks, and 9 weeks after the challenge infection, the lung tissues from each
group of mice were obtained and embedded in paraffin for 5-mm sections. The tissue sections were stained by immunohisto-
chemistry to detect the expression of interferon-gamma (IFN-g) and inducible nitric oxide synthase (iNOS) expression. (BeD and
FeH) the expression of IFNeg and iNOS, respectively, in the lung tissues from the PBST, rBCG-AE, and BCG groups at 9 weeks after
infecting the mice with M. tuberculosis H37Rv. (A and E) the negative controls in which PBS was added, instead of IFNeg or iNOS
antibody. The percentage of (i) positive IFNeg cells and (ii) positive iNOS cells in the lung tissues of mice vaccinated with BCG and
rBCG vaccine were obviously higher than the their percentage in the PBST group. There is no statistical difference among vaccine
groups (including the rBCGs and BCG groups). *p < 0.01, versus other groups. The arrows (➔) show the cells positive for IFNeg and
iNOS.
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the protective efficacy of BCG may be the following. One,
rBCG-AE is able to induce increased expression of IFN-g in
splenocytes8 but unable to stimulate the production of
IFN-g and iNOS in the lung tissues (which the results of
immunohistochemistry staining supported). This may be
the reason the rBCG-AE vaccine failed to elicit improved
protective efficacy. Two, ESAT-6 is a type of virulent
protein of M. tuberculosis27 and can inhibit T cell
responses and IFN-g production.28,29 Thus, the virulence
of rBCG-AE may increase and weight changes may reflect
the increased virulence since weight loss was greater in
the mice in the rBCG-AE group than in the BCG group
(Fig. 1C). The increased virulence was not conducive toimmune activation during immunostimulation. Three,
recent studies have reported that the protective efficacy
of BCG could be significantly promoted through rBCG
technology, and the parental BCG used in other experi-
ments was the BCG-Tokyo strain,30 the BCG-Danish
strain,31 or the BCG-Pasteur strain,32 whereas we chose
the BCG-China strain as the parental BCG in our study.
Researchers have found that different BCG strains induce
different immunity and have different unknown immune
mechanisms.33 Therefore, the choice of parental BCG has
a great effect on the immune efficacy of the rBCG
vaccine. Four, the methods of vaccination and the
administration dose are also critical in stimulating satis-
factory immune protection.
Protective efficacy elicited by a novel TB vaccine 55Much work may be needed to improve the protective
efficacy of rBCG vaccines such as (1) choosing other
parental BCG strains such as the BCG-Pasteur strain to
construct an rBCG vaccine; (2) utilizing better administra-
tion methods (e.g., intranasal vaccination) to induce
satisfactory immunization effects; (3) screening the
optimal dose for vaccination to induce better immune
responses; (4) changing immunization strategies to stimu-
late more potent immunity and thereby promote protective
efficacy; and (5) investigating why rBCG-AE is able to
significantly promote immunogenicity but not improve the
protective efficacy in comparison to the parental BCG. In
conclusion, our study suggested that an rBCG strain
expressing an Ag85A-ESAT-6 fusion protein can not promote
protective efficacy against M. tuberculosis H37Rv infection,
compared to the parental BCG.
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